Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01 eye drops, a topical candidate in Phase 3 for diabetic macular edema; OCS-02, a topical anti-TNFα eye drop candidate for dry eye disease; and OCS-05, a neuroprotective candidate for acute optic neuritis. Headquartered in Switzerland with operations in the US and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team and supported by leading healthcare investors.
